Kynurenate derivative attenuates the nitroglycerin-induced CamKIIα and CGRP expression changes

Headache
E VámosL Vecsei

Abstract

To examine the efficacy of L-kynurenine and a novel kynurenic acid derivative on the nitroglycerin-induced calmodulin-dependent protein kinase II alpha (CamKIIalpha) and calcitonin gene-related peptide (CGRP) expression changes in the rat caudal trigeminal nucleus. Systemic administration of the nitric oxide donor nitroglycerin can trigger an attack in migraineurs. In the rat, nitroglycerin activates second-order neurons in the caudal trigeminal nucleus, and increases expression of the CamKIIalpha and decreases that of the CGRP there. As glutamatergic mechanisms may be crucial in trigeminal pain processing, the aim of our study was to examine the effects of L-kynurenine, a metabolic precursor of the N-methyl D-aspartate receptor antagonist kynurenic acid, on the nitroglycerin-induced changes in CamKIIalpha and CGRP immunoreactivity. One hour before the nitroglycerin (10 mg/kg bodyweight, s.c.) injection, the animals were pretreated with L-kynurenine (300 mg/kg bodyweight, i.p.) or 2-(2-N,N-dimethylaminoethylamine-1-carbonyl)-1H-quinolin-4-one hydrochloride (300 mg/kg bodyweight, i.p.), a novel kynurenic acid derivative. Four hours later, the rats were perfused transcardially and the cervical spinal cord segments were removed fo...Continue Reading

References

Jun 1, 1985·Experimental Neurology·M N Perkins, T W Stone
Apr 1, 1987·Headache·F SicuteriA Bonazzi
Mar 1, 1981·Clinical Pharmacokinetics·R F CunninghamP G Dayton
Apr 1, 1995·Cephalalgia : an International Journal of Headache·J OlesenI J Olesen
Oct 24, 2000·Neurobiology of Disease·C J Woolf
Sep 14, 2001·Headache·P RoffeyD Thangathurai
Apr 5, 2002·The Biochemical Journal·Andy Hudmon, Howard Schulman
Jan 22, 2003·Trends in Neurosciences·Giles E Hardingham, Hilmar Bading
Jun 16, 2004·Cephalalgia : an International Journal of Headache·C N SangF Vandenhende
Oct 7, 2004·European Journal of Pharmacology·Udayasankar ArulmaniPramod R Saxena
Apr 29, 2006·Neuroscience Letters·Christina PrescottKathryn M Partin
Aug 25, 2006·Headache·Michael L Oshinsky, Jia Luo
Aug 19, 2007·CNS & Neurological Disorders Drug Targets·Michail Vikelis, Dimos D Mitsikostas
May 1, 2008·Journal of Neural Transmission·Eva RózsaJózsef Toldi
Jan 28, 2009·Cephalalgia : an International Journal of Headache·A FerrariA Bertolini
May 12, 2009·Expert Opinion on Investigational Drugs·Anna P Andreou, Peter J Goadsby

❮ Previous
Next ❯

Citations

Dec 17, 2010·Journal of Neural Transmission·J TajtiL Vécsei
Jun 7, 2011·Journal of Neural Transmission·Arpád PárdutzLászló Vécsei
Feb 11, 2014·The Journal of Headache and Pain·Charlotte KageneckMichael Jm Fischer
Sep 26, 2014·Expert Opinion on Drug Metabolism & Toxicology·János TajtiLászló Vécsei
Mar 12, 2011·Journal of Pharmaceutical and Biomedical Analysis·Dénes ZádoriAntal Péter
Dec 3, 2015·The Journal of Headache and Pain·A CsátiK Warfvinge
May 20, 2011·Cephalalgia : an International Journal of Headache·Song GuoMessoud Ashina
Nov 15, 2013·Therapeutic Advances in Neurological Disorders·Zsófia MajláthLászló Vécsei
Oct 30, 2015·Cephalalgia : an International Journal of Headache·Gábor Nagy-GróczÁrpád Párdutz
Dec 6, 2016·Cephalalgia : an International Journal of Headache·Rosaria GrecoCristina Tassorelli
May 1, 2016·The Journal of Headache and Pain·Martina CurtoPaolo Martelletti
Mar 24, 2016·The Journal of Headache and Pain·Martina CurtoPaolo Martelletti
Nov 30, 2018·Expert Opinion on Emerging Drugs·Giorgio LambruPaolo Martelletti
Dec 15, 2012·Nature Reviews. Drug Discovery·László VécseiJózsef Toldi
Mar 20, 2012·Journal of Neural Transmission·J TajtiL Vécsei
Jan 5, 2011·Journal of Neural Transmission·Dénes ZádoriPéter Klivényi
Dec 16, 2010·Journal of Cellular and Molecular Medicine·Dénes ZádoriLászló Vécsei
Sep 29, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Evelin FehérJózsef Toldi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.